

GTX

[View the current GTX Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32439-GTX.html) (<http://www.bioportfolio.com/biocorporate/32439-GTX.html>)

Contact Details:

3 North Dunlap Street

Memphis

Tennessee

38163

United States of America

Tel: 901.523.9700 Ext.170

Fax: 901.523.9772

Email: investor.relations@gtxinc.com

GTx, Inc., headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel hormonal therapeutics for cancer and serious conditions related to men's health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx is developing ACAPODENE® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial evaluating ACAPODENE® 80 mg for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial evaluating ACAPODENE® 20 mg for the prevention of prostate cancer in high risk men with the premalignant lesion known as high grade prostatic intraepithelial neoplasia. GTx has licensed to Ipsen Group exclusive rights in Europe to develop and commercialize ACAPODENE®. GTx also is developing ostarine, a first-in-class selective androgen receptor modulator, or SARM. GTx believes that ostarine has the potential to treat a variety of indications, including cancer cachexia, end stage renal disease muscle wasting, frailty and osteoporosis. GTx plans to initiate a Phase IIb ostarine clinical trial for cancer cachexia by the summer of 2007. GTx also has an extensive preclinical pipeline generated from a world-class discovery program which includes the specific product candidates prostarine, a SARM for benign prostatic hyperplasia, and andromustine, an anticancer product candidate, for hormone refractory prostate cancer.

Recent Publications by GTX:



- [Recent and emerging anti-diabetes targets.](#)

Diabetes is a disease that affects over 150 million people worldwide for... 16th October, 2008

Preclinical Research and Development, GTx, Inc., 3 N. Dunlap St., Memphis- Med Res Rev. 2008 Oct 14. ([DOI Direct Link](#))

- [Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways.](#)

- Androgen receptor (AR) ligands are important for the development and...* 20th September, 2008
Preclinical Research and Development, GTx, Inc., 3 North Dunlap Street,- Mol Endocrinol. 2008
Nov;22(11):2448-65. Epub 2008 Sep 18. ([DOI Direct Link](#))
- [Preclinical Characterization of a \(S\)-N-\(4-Cyano-3-trifluoromethyl-phenyl\)-3-\(3-fluoro, 4-chlorophenoxy\)-2-Hydroxy-2-Methyl-Propanamide: A Selective Androgen Receptor Modulator for Hormonal Male Contraception.](#)
The pharmacologic effects of... 6th September, 2008
Division of Pharmaceutics, College of Pharmacy, The Ohio State University,- Endocrinology. 2008 Sep 4. ([DOI Direct Link](#))
 - [Vitamin D3-24-hydroxylase \(CYP24\) as a potential target for intervention with diabetic and nondiabetic nephropathy.](#)
The pharmacologic effects of... 16th March, 2007
GTx Pharmaceuticals, Griobenzell, Germany.- Clin Lab. 2007;53(1-2):85-8.
 - [Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay.](#)
Several methods to assess genotoxicity of physical and chemical agents... 27th January, 2007
Cytomation GTx Inc., Fort Collins, CO, USA.- Mutat Res. 2006 Dec 1;602(1-2):14-25. Epub 2006 Oct 11. ([DOI Direct Link](#))
 - [Rhabdovirus assembly and budding.](#)
Rhabdoviruses are a diverse, widely-distributed group of enveloped viruses... 1st March, 2005
GTx Inc., 3 N. Dunlap, Van Vleet Research Building, Memphis, TN 38163,- Virus Res. 2004 Dec;106(2):117-32. ([DOI Direct Link](#))
 - [The membrane-proximal region of vesicular stomatitis virus glycoprotein G ectodomain is critical for fusion and virus infectivity.](#)
The glycoprotein (G) of vesicular stomatitis virus (VSV) is responsible... 6th January, 2004
Department of Molecular Sciences, University of Tennessee Health Sciences- J Virol. 2003 Dec;77(23):12807-18.

BioNews Results for GTX



- [Global Therapeutics initiates trial of stent with RNA therapeutic agent to prevent artery closure](#)
MTB Europe: Nov 18 2008 6:14PM Matching: gtx
- [Life Sciences: Scientists at GTx publish research in life sciences](#)
NewsRX: Nov 18 2008 2:10PM Matching: gtx
- [Global Therapeutics Initiates Trial of RNA Coated Drug-Eluting Stent](#)
Diagnostic & Invasive Cardiology: Nov 12 2008 9:36AM Matching: gtx
- [GTx Announces Corporate Presentation at Lazard Capital Markets Annual Healthcare Conference](#)
DiGiTAL50: Nov 11 2008 8:36PM Matching: gtx
- [GTx Announces Corporate Presentation at Lazard Capital Markets Annual Healthcare Conference](#)
Pharma Live: Nov 11 2008 1:23PM Matching: gtx
- [Global Therapeutics Initiates Trial Of Next Generation Drug-Eluting Stent Using RNA Therapeutic Agent To Treat](#)
Medical Design Online: Nov 11 2008 9:32AM Matching: gtx
- [Next Generation Drug-Eluting Stent Uses RNA Therapeutic Agent to Treat Coronary Artery Disease](#)
Nanowerk: Nov 11 2008 6:12AM Matching: gtx
- [Stent Trial Aims to Silence Restenosis Gene](#)
Medical Device Link: Nov 11 2008 2:25AM Matching: gtx

- [AVI BioPharma Announces Initiation of Clinical Trial of Next Generation Drug Eluting Stent by Partner Global T](#)
Genetic Engineering News: Nov 10 2008 4:33PM Matching: gtx
- [AVI BioPharma Announces Initiation of Clinical Trial of Next](#)
Market Wire via MSN Money: Nov 10 2008 1:27PM Matching: gtx
- [Global Therapeutics Initiates Trial of Next Generation Drug-Eluting Stent Using RNA Therapeutic Agent to Treat](#)
Pharma Live: Nov 10 2008 4:06PM Matching: gtx
- [Global Therapeutics Initiates Trial of Next Generation Drug-Eluting Stent Using RNA Therapeutic Agent to Treat](#)
Genetic Engineering News: Nov 10 2008 2:29PM Matching: gtx
- [GTx, Inc. Reports Third Quarter 2008 Financial Results](#)
DiGiTAL50: Nov 7 2008 3:58AM Matching: gtx
- [GTx, Inc. Reports Third Quarter 2008 Financial Results](#)
Genetic Engineering News: Nov 6 2008 12:59PM Matching: gtx
- [GTx Announces Corporate Presentation at Rodman & Renshaw Annual Healthcare Conference](#)
DiGiTAL50: Nov 4 2008 8:28PM Matching: gtx

GTX Patents:



- 7016536- [Method and apparatus for automatic cleaning and enhancing of scanned documents](#)
- 6873436- [Image processing device and recording medium](#)
- 4989257- [Method and apparatus for generating size and orientation invariant shape features](#)
- 4975975- [Hierarchical parametric apparatus and method for recognizing drawn characters](#)
- 4949388- [Method and apparatus for recognition of graphic symbols](#)
- 4821336- [Method and apparatus for simplifying runlength data from scanning of images](#)
- 4817187- [Apparatus and method for vectorization of incoming scanned image data](#)
- 4802230- [Method and apparatus for generating size and orientation invariant shape features](#)
- 4797806- [High speed serial pixel neighborhood processor and method](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search

- engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

